EUVIMEDEUVIMED entdecken
Crossref

Perspective on Tumor Organoids in Drug Screening and Cancer Precision Medicine

Lingzhi Wang

Journal of Organoid and Bioscience · 2024

DOI: 10.62714/zlsh6629 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Organoid and Bioscience, 2024. Verfasst von Lingzhi Wang.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The landscape of cancer research is swiftly evolving, presenting fresh optimism through innovative tactics that customize treatment for each patient. In 2016, Clevers unveiled a groundbreaking study in Cell, introducing organoids that emulate essential structural and functional traits of organs like the kidney, lung, gut, brain, and retina. This technology enables the replication of human organ development and various pathologies within a controlled laboratory environment. Mounting evidence underscores the potential of patient-derived organoids (PDOs) to reshape cancer treatment and revolutionize drug discovery in oncology. This commentary explores these pioneering research avenues and their profound implications for clinical oncology and pharmaceutical development.

Zitieren

APA

Wang, L. (2024). Perspective on Tumor Organoids in Drug Screening and Cancer Precision Medicine. Journal of Organoid and Bioscience. https://doi.org/10.62714/zlsh6629

Vancouver

Wang L. Perspective on Tumor Organoids in Drug Screening and Cancer Precision Medicine. Journal of Organoid and Bioscience. 2024. doi:10.62714/zlsh6629

BibTeX
@article{Wang2024,
  author = {Wang, Lingzhi},
  title = {Perspective on Tumor Organoids in Drug Screening and Cancer Precision Medicine},
  journal = {Journal of Organoid and Bioscience},
  year = {2024},
  doi = {10.62714/zlsh6629}
}
Kostenlos starten →